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LIST of abbreviations 
 
Drug  abbreviations. SOF: sofosbuvir.  LDV: ledipasvir.  DCV: daclatasvir.  VEL: velpatasvir.  GZR: 
grazoprevir.  EBR: elbasvir.  SIM: simeprevir.  3D: Paritaprevir/r, ombitasvir, dasabuvir.  2D: 
Paritaprevir/r, ombitasvir  
 
Other abbreviations. HCV: hepatitis c virus.  LT: liver transplantation.  PEG-IFN: pegylated 
interferon.  DAA: direct acting agents. DDI: drug to drug interactions. SVR: sustained virologic 
response. RAS: resistance associated substitution. AUC: area under the curve. M-TOR: 
mammalian target of rapamycin. LLOQ: lower level of quantification. HBV: hepatitis B virus. 
SmPC: summary of product characteristics. CsA: Cyclosporin. TAC: tacrolimus. MMF: 
micophenolate-mofetil. CNI: calcineurin inhibitors. IS: immunosuppressants. CNS: central 
nervous system. FCH: fibrosing cholestatic hepatitis. 
  
 
 
3
3
 
 
The first version of these clinical practice guidelines was presented at the “ELITA Symposium” 
held in Brussels on September 13, 2015.  
 
 
ABSTRACT 
The advent of safe and highly effective direct acting antivirals (DAA) had huge implications for 
the HCV transplant field and changed our management of both, patients on the waiting list and 
those with HCV graft reinfection after Liver Transplantation (LT).  When treating HCV infection 
before LT, HCV reinfection of the graft may be prevented in nearly all patients. In addition some 
candidates show a remarkable clinical improvement and are possibly delisted.  
Alternatively, HCV infection can be treated post LT either soon after the transplant, taking 
advantage of the removal of the infected native liver, or at the time of disease recurrence as done 
in the past.  In either case, some DAAs would have a limited use due to the frequent drug to drug 
interactions with various immunosuppressants  and the many other drugs liver transplant 
recipients are often prescribed. In addition, some DAAs should be avoided in case of severe renal 
failure, which is not an unusual complication after LT.  
The present document provides a series of “consensus statements” on the fore-mentioned LT 
issues that have not been extensively addressed previously. These statements have been 
developed in order to be of support to physicians and other stakeholders in charge of LT 
candidates and recipients when deciding to treat Hep C especially in difficult situations. 
  
 
 
4
4
 
Background 
 
Chronic hepatitis C virus (HCV) infection related advanced liver disease is the most 
common  indication for liver transplantation (LT) which accounts for about 10% to 50% of LTs 
performed in northern and southern Europe, respectively (www.ELTR.org).  Until very recently 
all HCV recipients who underwent LT had detectable viremia.  Virtually all of them had HCV re-
infection shortly after transplant.  Between 10% to 30% developed cirrhosis within 5 years from 
LT and 40% presented signs of liver decompensation within 1 year from the diagnosis of 
recurrent cirrhosis (1-3).  The combination of PEG-IFN and ribavirin has been the only 
therapeutic option available for the last 20 years but it was rarely effective, particularly in 
patients with more advanced graft hepatitis.  Due to the high risk of severe disease recurrence, 
re-transplantation was controversial in case of HCV-induced graft failure.  All these facts explain 
why HCV infected recipients had a reduced survival rate by at least 10% after 5 years of follow 
up, compared to non HCV infected individuals (4). 
The advent of safe and highly effective direct acting antivirals (DAA) had huge 
implications for the HCV transplant field and changed our management of both, patients on the 
waiting list and those with HCV graft reinfection after LT.  When treating HCV infection before 
LT, some candidates show a remarkable clinical improvement and are possibly delisted.  If not, 
HCV reinfection of the graft may be prevented in nearly all patients when a HCV RNA negative 
status is achieved by DAAs at least 4 weeks before transplantation (>95%). 
Alternatively, HCV infection can be treated post LT either soon after the transplant, taking 
advantage of the removal of the infected native liver, or at the time of disease recurrence as done 
in the past.  In either case, some DAAs would have a limited use due to the frequent drug to drug 
interactions (DDI) with various immunosuppressants (IS) and the many other drugs liver 
transplant recipients are often prescribed. In addition, some DAAs should be avoided in case of 
severe renal failure, which is not an unusual complication after LT.  
Finally, anti HCV positive donors with favorable histological features are likely to become 
an additional important resource for the donor pool particularly in areas the anti-HCV positive 
donors are more prevalent. The potential recipients of these grafts should be selected 
beforehand and treated after LT. 
 
In the middle of this therapeutic revolution, two monothematic ELITA Conferences were 
held in Milan in March 2015 and April 2016  where  a selected number of European experts 
discussed the many unsolved issues regarding the use of DAAs before and after liver 
transplantation.  The present document provides the conclusions of these Conferences which are 
now included in these ELITA statements. 
 
 
Methodology  
The ‘‘Clinical practice guidelines’’ were elaborated following a slightly modified AGREE 
methodology (5). In brief, the promoter of this initiative was ELITA (European Liver and 
Intestine Transplant Association) which selected a scientific board of experts in charge of 
organizing the two Conferences held in Milan and of writing this document. The two Conferences 
were endorsed by the Italian Association for the study of the Liver (AISF) and by the European 
Association for the Study of the Liver (EASL). The scientific board defined the methodology 
utilized as well as the goals, and acted as developer and reviewer. The methodology chosen 
involved the following steps: 
 
(a) The scientific board selected thirteen topics of interest and relevant questions regarding both 
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clinical practice and controversial areas. 
(b)  The scientific board also identified two working groups. The first addressed the issues 
related to “the management of the patient on the waiting list”, the second “the treatment of post 
transplant HCV disease recurrence”.  The two working groups were composed of five experts 
guided by a group leader. The members of the two working groups were selected on the basis of 
competence, role, expertise and publications/research in the field of HCV and LT.  
(c)  The two group leaders together with the scientific board elaborated the provisional 
statements. All questions and provisional statements were circulated among the experts of each 
working group before the Conferences were held in Milan. This policy allowed each expert to 
independently carry out a systematic literature search, using Medline/ PubMed to support 
definitions and statements.  
(d) The statements were discussed among the experts of the two working groups during 2 
conferences held in Milan on 6th March 2015 and April 1rst, 2016 with the purpose to improve 
the quality of the statements. The two Conferences were videoed and all relevant comments 
were taken into account when preparing the final document. 
 (f) The scientific board prepared a draft of “Clinical Practice Guidelines” which incorporates the 
conclusions of the two Milan Conferences as well as the relevant data from existing publications 
and presentations at international meetings up to April 2016. For each of the 13 issues, a short 
background and a summary of the evidence is presented. The evidence and recommendations 
have been graded according to the Grading of Recommendations Assessment Development and 
Evaluation (GRADE) system (5). Table 1 
(g) The first draft of the Clinical Practice Guidelines was eventually submitted to the experts of 
the working groups for corrections, comments and approval of the recommendations. Following 
a Delphi process the experts were asked to specify whether they approved each 
recommendation and, if not, to justify their disagreement. Corrections and comments were taken 
into account in the final version of the Clinical Practice Guidelines. Agreement among experts 
was very high (96%).  
(h) The promoter, and all members of the scientific board and working groups were asked to 
declare any potential conflict of interests.  
The questions selected by the scientific board are listed below: 
 
Pre transplant phase. 
 
1. Which DAAs should be used in cirrhotic patients listed for LT? 
2. Which treatment schedules should be used in listed patients and what are the expected 
Sustained Virologcal Responses  (SVR)? 
3. What is the impact of pre LT DAAs on liver function and delisting?  
4. Who should be treated or not treated before LT - patients with de-compensated cirrhosis.  
5. Who should be treated or not treated before LT- patients with compensated cirrhosis and HCC 
6. Is  DAA therapy given across LT  (“bridging therapy”) a valuable option? 
7. How to manage DAA treatment failures and when is detection of resistance associated 
substitutions (RAS) a concern? 
  
Post transplant phase. 
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8. Which DAAs should be used after LT?  The role of liver function, renal function and DDI.  
9. What rate of SVR is expected after treating patients for HCV disease recurrence?  
10.  What is the best timing for DAA treatment after LT?   
11. Can HCV therapy be expected to have a beneficial impact on extra-hepatic manifestations of 
HCV? 
12. Is re-transplantation of HCV-infected recipients a reliable option under DAA therapy? 
13. Can HCV-positive donors be used more extensively? 
 
 
 
 
CLINICAL PRACTICE GUIDELINES. 
A. Pre transplant phase. 
 
Q1. Which DAAs should be used in cirrhotic patients listed for LT? 
 
Background 
DAAs should be used with caution in LT candidates with severely impaired liver function (Child-
Pugh B and C) or with severe renal dysfunction (estimated GFR< 30 mL/min) as both conditions 
may affect the metabolism of some DAAs. 
 
Facts 
a. Impairment of liver function affects the exposure of various DAAs which is typically measured 
by the area under the curve (AUC) (Table 2).  
Simeprevir (SIM): AUC increased by 2.5 fold in Child-Pugh B and 5.2 fold in and Child-Pugh C. 
Paritaprevir/r (ABT 450/r): AUC increased by almost 10 folds in Child-Pugh C. Dasabuvir: AUC 
increased by 4-fold in Child-Pugh C but not in Child B. Sofosbuvir (SOF): AUC increased by 2-fold 
both in Child-Pugh B and C. Grazoprevir (GZR): AUC increased by 2 to 3-fold in Child-Pugh B 
while there are no data to date for Child-Pugh C.  Ledipasvir (LDV) and Velpatasvir (VEL): AUC not 
affected by reduced liver function. 
b. Impairment of renal function impacts mainly the kinetics of the inactive metabolite of 
sofosbuvir, SOF007, which accumulates when the estimated GFR is below 60 mL/min. (Table. 
2).  In absence of sufficient safety data, the SOF summary of product characteristics (SmPC) 
warns against its use if eGFR is below 30mL/min.  
c. Some DAAs share transport and metabolic pathways with several other drugs, including 
among others calcineurin, mTOR inhibitors and anti-retrovirals, which can cause strong DDI. The 
potential risk of DDI should be carefully taken into account before deciding on the most 
appropriate DAA regimen. 
d. In patients with decompensated cirrhosis, ribavirin can be started at the dose of 600 mg daily and the 
dose subsequently adjusted depending on tolerance. The dose of ribavirin should be adjusted 
downward by 200 mg at decrements if the haemoglobin level drops below 10 g/dl. Ribavirin 
administration should be stopped if the haemoglobin levels drops below 8.5 g/dl 
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Pre LT recommendations 
 
1.  SOF, LDV, VEL and Daclatasvir (DCV) can be used in patients with cirrhosis with no need of 
dose adjustment, regardless of liver impairment. GRADE I 
Comment A note of caution is suggested when using DAA in patients with severe liver disease 
(Child-Pugh C or MELD > 20) due to limited experience  
 
2. The 3D combo (Paritaprevir/r, ombitasvir, dasabuvir) and the 2D combo (Paritaprevir/r, 
ombitasvir) should not be used in patients with decompensated cirrhosis (Child-Pugh B and C). 
SIM is not recommended in patients with moderate hepatic impairment (Child-Pugh B) and 
should be avoided in Child-Pugh C. GRADE I The 3D, 2D combo, SIM and GZR/EBR can be safely 
used only in patients with compensated cirrhosis  (Child-Pugh A). GRADE II-2 
 
3. In case of pre LT eGFR below 30 mL/min, SOF should be preferably planned after LT.  GRADE 
III 
 
4. DDI between a specific DAA and any other co-administered drug, should be carefully 
evaluated when planning any antiviral regimen.   
Comment. Possible DDI should be checked on international websites 
(www.hepcdruginteractions.com) or discussed with a clinical  pharmacologist GRADE III 
 
 
Q2. Which treatment schedules are recommended for listed patients and what are the 
expected SVR? 
 
Background 
According to the Guidelines released by EASL and AASLD (6-8) different DAA regimens result in 
very high SVR rates even in patients with decompensated cirrhosis. Currently, many of these 
patients are treated while on the waiting list although it is not entirely clear how many of them 
will achieve  viral eradication post LT.  To date this issue has been addressed by a single study 
(9) which enrolled patients with compensated cirrhosis who were treated with a single DAA, 
SOF, in combination with Ribavirin. 
 
Facts 
Many studies have explored the efficacy of DAAs in terms of SVR in patients with various degrees 
of clinical decompensation (Table 3).  Afdhal et al. (10) found that the combination of SOF/RBV 
for 48 weeks given to 50 Child-Pugh A or B, genotype 1 or 4, was associated with a 72% SVR 
overall (78% in Child-Pugh A and 68% in Child-Pugh B).  
In SOLAR 1 study (11), the combination of SOF/LDV+RBV (600 mg, increased as tolerated) given 
to 108 patients with decompensated cirrhosis and infected with genotype 1 or 4, resulted in 
SVR-12 rates between 85 and 89%, irrespective of Child-Pugh class (B or C) and of treatment 
duration (12 or 24 weeks).  In SOLAR 2 study (12) the same combination of SOF/LDV+RBV (600 
mg, increased as tolerated)  given to 160 cirrhotic patients for 12 or 24 weeks resulted in an 
SVR12 of 87-96% in Child-Pugh B patients and 72-80% in Child-Pugh C.  The UK early access 
programme (13) on 467 Child-Pugh B or C patients, reported an overall SVR12 in 80% and 74% 
of patients treated with SOF/LDV +/- RBV or SOF/DCV+/- RBV (600 mg, increased as tolerated) 
for 12 weeks, respectively.  Finally, the combination of SOF/VEL +RBV (1000-1200 mg) for 12 
weeks in decompensated cirrhosis (mainly Child-Pugh B) resulted in an 85% SVR rate which was 
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superior to the 50% SVR rate achieved by combining SOF/VPV without RBV for 12 weeks or 24 
weeks (14).  
 
Looking at specific genotypes, the SVR12 was 80% in HCV genotype 1 or 4 with slightly higher 
SVR 12 rates when RBV was added. For HCV genotype 3 infected patients, the SVR12 was 
approximately 60% in those treated with SOF/LDV and 70% of those treated with SOF/DCV. 
(13) 
 
The combination SOF+DCV+RBV (600 mg) for 12 weeks was also assessed in 113 pre and post 
LT patients with cirrhosis (any genotype) in the Ally1 study (15) which showed SVR12 rates of 
92% in Child-Pugh A, 94% (30/32) in Child-Pugh B and 56% (9/16) in Child-Pugh C.  Finally, 
another study of 55 genotype 1 patients treated with SOF+SIM showed SVR 4 rate of 75% (16).   
In HIV co-infected patients, efficacy and tolerability of DAA treatments was similar to that 
observed in HCV monoinfected patients (17-18).  
The effects of DAA given pre LT on post LT recurrence were explored in a single study by Curry 
et al. (9) who treated  61 HCC patients with Child-Pugh A cirrhosis with SOF/RBV. All patients 
were infected with genotypes 1 or 4 and were treated for either 48 weeks or until LT. The “on 
treatment” response was very high (93% had HCV-RNA less than the lower level of 
quantification (LLOQ) at week 4) and post LT SVR 12 was achieved in 70% of treated patients. In 
the same study a “post hoc” analysis showed a dramatic post-LT SVR 12 of 96% in the subgroup 
of 29 patients that had remained HCV-RNA negative for at least 30 days before LT.  Indeed, of the 
29 patients who had HCV-RNA below LLOQ for at least 30 days, only one (3%) suffered HCV 
recurrence after LT compared to 9 out 14 patients (64%) of those who had HCV-RNA below 
LLOQ for less than 30 days.  These results suggest that the removal of the infected liver, once a 
viral clearance of at least 1 month duration has been achieved, is adequate for preventing HCV 
recurrence after LT and it indicates that achievement of SVR is not a mandatory end-point for all 
listed patients.  To date this is the only study addressing virologic response profiles or kinetics 
required to prevent post LT HCV recurrence. 
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Pre LT recommendations 
 
5. DAA therapy can be considered in patients who are listed for LT; virological response after 
DAA therapy is very high, in the order of 90%, in patients with compensated cirrhosis (Child-
Pugh A) and high, in the order of 80%, in those with decompensated cirrhosis (Child-Pugh B-C) 
and is not influenced by HIV co-infection. GRADE I 
 
6. The duration of DAA treatment should be as short as possible and DAA combinations 
achieving a SVR in 12 weeks should be preferred. GRADE III 
 
7. A serum HCV RNA negative status (LLOQ) for at least 1 month before LT seems to be a reliable 
virologic end-point if prevention of HCV recurrence is the main treatment goal. Nevertheless, LT 
should not be postponed because of only short ongoing pre-LT DAA therapy, in case an organ 
becomes available. GRADE III  
Comment. To date this virologic end-point has only been verified in patients with Child-Pugh A 
cirrhosis and therefore needs to be confirmed in patients with decompensated cirrhosis.  
 
8.   First line treatment options for listed patients according to specific genotypes are the 
following:  
- Genotype 1/4. SOF/LDV+RBV (600 mg, increased as tolerated)  or SOF+DCV+RBV for 12 weeks 
irrespective of liver function (Child Pugh A, B and C). SOF/VEL without RBV for 12 weeks in 
Child Pugh A and with RBV (1000-1200 mg) in Child-Pugh B and C.  If patients do not tolerate 
RBV, the duration of SOF/VEL should be extended up to LT or to a maximum of 24 weeks. Other 
possible options for Child-Pugh A patients with genotype 1 are:  SOF+SIM+RBV (600 mg, 
increased as tolerated) or 2D + RBV (600 mg, increased as tolerated) for 12 weeks or GZR/EBR 
for 12 weeks in HCV G1b, or GZR/EBR plus ribavirin for 16 weeks in HCV G1a patients. Finally in 
patients Child-Pugh A genotype 4 , 3D with (600 mg increased as tolerated) or without RBV for 
24 weeks are equally valuable options. GRADE I 
- Genotype 2. SOF+DCV for 12 weeks or SOF/VEL for 12 weeks are the preferred regimen for any 
listed patient infected with genotype 2 due to its short duration. In patients with Child-Pugh B or 
C RBV should be added.  GRADE I 
-  Genotype 3. SOF/VEL + RBV (1000-1200 mg) for 12 weeks (Child-Pugh A, B) or SOF+DCV+RBV 
1000-1200 mg for 12 weeks irrespective of liver function (Child-Pugh A, B and C).  If patients do 
not tolerate RBV the duration of treatment of SOF/VEL or SOF+DCV can be extended up to LT or 
to a maximum of  24 weeks. GRADE II-2.  
- Genotype 5-6. The same regimens with SOF/VEL, SOF/LDV or SOF+DCV suggested for genotype 
1 or 4 should be used for genotypes 5 and 6 although data are limited. GRADE II-1 
 
9.  In HIV co-infected patients, the treatment options are identical to HCV mono-infected  
patients provided that DDI with concurrent antiretroviral therapy are taken into account . 
GRADE II-2 
 
 
Q3. What is the impact of DAAs on liver function and de-listing? 
 
Background  
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Up to one third of HBV patients with decompensated cirrhosis treated with Nucleos(t)ides drugs 
while listed for LT, can be eventually delisted within 1 year due to clinical improvement and, 
once delisted, they maintain their clinical improvement for up to 5 years (19).  A critical issue is 
therefore to determine whether DAA treatment can also achieve similar results in HCV 
candidates with decompensated cirrhosis.  The advantage of delisting HCV candidates would be 
twofold: for the patient who is delisted as he no longer needs a liver transplant and for the donor 
pool as an organ becomes available for another recipient. 
 
Facts 
Changes in liver function after DAA therapy given to patients with decompensated cirrhosis have 
been investigated in a limited number of studies (11-16), only 2 of which  did not pool the pre 
and post transplant data together (12,16).  
In the SOLAR 1 study (11) the combination of SOF/LDV+RBV was given for 12 or 24 weeks to 
108 patients with decompensated cirrhosis and with genotype 1 or 4 infection.  A decrease in 
Child-Pugh score of at least 2 points from baseline to post-treatment week 4 was observed in 
about 40% of the patients. This result was not influenced by the length of the treatment.  These 
findings were also confirmed by the SOLAR 2 study (12).  
In the ALLY 1 study (15), 48 decompensated cirrhotics (32 Child-Pugh B and 16 Child-Pugh C) 
were treated with SOF+DCV+RBV for 12 weeks.  All 48 patients but 1 had a MELD < 25.  Six of the 
30 Child-Pugh B patients (20%), showed a decrease greater than 3 points in MELD at SVR 12.  
Among the 14 Child-Pugh C patients, a similar rate of improvement was observed in 3 cases 
(3/14, 21%). The study did not consider possible predictors of improvement nor the possibility 
of delisting. Virtually no patients with MELD score > 25 was considered eligible for DAA 
treatment in either study. 
A study from France (20) explored the issue of delisting due to clinical improvement in 77 
decompensated cirrhotics from 18 Centres. Patients were treated with various combinations of 
DAAs (SOF+DCV or LDV or SMV with or without RBV) for 12 or 24 weeks.  Twelve patients 
(16%) were delisted due to clinical improvement. A similar delisting rate (18%) was reported in 
another study from Spain where 20 patients of the 110 treated with various combination of 
DAAs were delisted (21). A third European study promoted by ELITA (22) found that 21 of 103 
(20.4%) patients with decompensated cirrhosis could be delisted due to clinical improvement 
after a median period of 60 weeks.  The probability of being delisted was very high in patients 
with a MELD <16 (about 35%) and minimal in those with a MELD >20 (about 5%). All delisted 
patients had either a complete regression or a dramatic improvement of signs of hepatic de-
compensation such as ascites and/or hepatic encephalopathy. Improvement of the MELD score 
by at least 3 points and of albumin by at least 0.5 gr/dL after 12 weeks of DAA, emerged as useful 
additional independent dynamic predictors of inactivation on the waiting list (Fig 1) and 
subsequent delisting. Despite these favourable results a word of caution is required for the 
following two reasons: 1. in candidates with high MELD score, a MELD decrease not sufficient for 
delisting may work at disadvantage for the patient that looses priority on the waiting list (MELD 
purgatory). 2. no data are yet available  on how long the clinical improvement will last and on 
how many patients will develop a HCC after delisting.  On the other hand, a drop of 2 to 3 points 
of MELD may be beneficial for the LT candidate by reducing the risk of mortality on the waiting 
list particularly in those with a medium/high MELD score and/or an expected prolonged waiting 
time.  
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Pre LT recommendations 
 
10. Patients with decompensated cirrhosis and a MELD score < 20 on the waiting list should be 
considered for DAA therapy because around 20% of them can improve their liver function to an 
extent that they can be delisted. GRADE II-3 
Comment: The benefit of delisting would be 2-fold, since a liver not used for a patient that is 
delisted can be offered to another LT candidate.   
 
11. A minimal treatment period of 3 months should be considered before inactivation and 
delisting  since the probability of being delisted due to clinical improvement depends not only on 
the MELD score before starting DAA therapy but also on MELD score and albumin improvements 
after 12 weeks of therapy (details are given in recommendations 14 to 18).  GRADE II-3 
 
12 In patients with high MELD scores (>20) and expected prolonged waiting time, the risk of a 
MELD purgatory effect should be balanced against the benefit of reducing the risk of death on the 
waiting list intrinsically associated with MELD reduction.   
Comment A word of caution is required concerning possible side effects in patients with very 
advanced disease (MELD > 20)  since DAA experience in treating these patients  is very limited  
 
 
 
Q4. Patients listed for decompensated cirrhosis (without HCC): who should be treated or 
not treated before LT? 
 
Background 
To establish whether pre LT DAA therapy is justified, the following factors should be considered: 
- the risk of death on the waiting list, which is proportional to the MELD score. 
- the possibility of clinical improvement after DAA, which may favour the delisting of some 
patients , typically those with low MELD scores.   
- the awareness that a mild improvement in MELD score after DAA may not be enough for 
delisting and may work as a disadvantage for patients that lose priority on the waiting  list. This 
MELD purgatory effect is typically observed in patients with high MELD scores. 
- cost-effectiveness considerations. 
- potential side effects as some case series show liver failure during DAA +/- RBV 
- local epidemiology and HCV-positive donor policies  Fig.2 
Being aware of these factors will limit futile DAA treatment. 
 
Facts 
A significant decrease in either Child-Pugh or MELD score has been reported in 20% to 40% of 
patients with decompensated cirrhosis treated with DAAs.  However this improvement may not 
be sufficient for delisting, particularly in Child-Pugh C patients with high MELD scores where the 
MELD purgatory effect is likely to be the highest. Factors associated with liver function 
improvement and further delisting while on treatment have been discussed above (Question 3, 
facts).  
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Pre LT recommendations 
 
13. Patients with baseline MELD <16 (typically Child-Pugh B) have a high chance (35%) of being 
delisted due to clinical improvement and therefore should be treated while listed GRADE II-3 
Comment: Currently, the follow up of delisted patients is very short, therefore a word of caution 
is to be mentioned regarding how long the clinical improvement will last and how many patients 
will develop an HCC 
 
14. Patients with baseline MELD between 16 and 20 (mostly Child-Pugh C) 
a. These patients have a chance of being inactivated due to clinical improvement of about 12%. 
They should be started on DAA while listed and the possible clinical improvement should be 
assessed after 12 weeks of therapy.  GRADE II-3 
b Patients showing a significant improvement of MELD score >3 points and albumin > 0.5g/dL 
after 12 weeks on DAA should be maintained on the waiting list but in inactive position and 
considered for possible delisting during the follow up.  
c. Patients without a significant improvement in MELD and albumin after 12 weeks on DAA 
should be maintained in active position on the waiting list. (B1). GRADE II-3 
 
15. Patients with baseline MELD between 21 and 25 (typically advanced Child-Pugh C). A 
minority of these patients, specifically those with ACLF, may undergo a substantial clinical 
improvement after DAA treatment which makes inactivation on the waiting list still possible. For 
such patients a case by case multidisciplinary decision is advised. GRADE II-3 
Comment. Since a limited MELD improvement not leading to inactivation may hamper access to 
LT, patients should be maintained with their baseline MELD as assessed before DAA therapy in 
order to counteract the MELD purgatory effect. Such a MELD exception rule should be 
implemented after agreement with the Organizations for Organ Procurement. In addition, this 
candidates might benefit from receiving a graft from a suitable anti-HCV +ve donor. 
 
16. Patients with high MELD scores > 25. Based on current studies and practice, pre LT DAA 
treatment of these candidates is not recommended because of their poor prognosis with a 
significant risk of death either pre and post-LT, unknown probability of improvement, potential 
DAA toxicity and rapid access to LT. The option of post LT treatment with DAAs is therefore 
preferable. GRADE III 
Comment In addition, this candidates might benefit from receiving a graft from a suitable anti-
HCV +ve donor. 
 
 
Q5.Patients listed for hepatocellular carcinoma (HCC): who should be treated or not  
before LT? 
 
Background 
Patients listed for HCC frequently have a compensated liver cirrhosis and therefore can easily 
tolerate DAA treatment administered to prevent HCV recurrence after LT. This aspect is 
particularly relevant in countries where old donors are preferentially given to HCC patients with 
relatively preserved liver function.  
 
Facts 
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The 1-yr rate of removal from the liver transplant waiting list due to tumour progression is 
estimated to be up to 10% in Centres following the “Milan criteria” and up to 20% in those 
following “extended criteria”.  Similarly, the risk of dying of HCC recurrence after LT is up to 10% 
in centres adopting the Milan criteria and up to 20% in those adopting extended criteria. The 
response to therapeutic interventions for HCC while the patient is on the waiting list further 
affects prognosis either pre and post LT.  These competing risks should be taken into account in 
order to avoid futile DAA treatment (Fig.2)  
The present scenario is further complicated by the recent alert regarding a possible increased 
risk of HCC recurrence in patients who cleared HCV with DAAs after achieving a complete HCC 
eradication following resection or local ablation. As the available data are conflicting, properly 
designed studies are urgently needed to address this relevant issue (23-26) 
 
Pre LT recommendations.  
 
17. In patients listed for HCC, pre LT treatment should be restricted to those with the following 
features: a) a low risk of post-transplant HCC recurrence, whatever model is used to assess the 
risk (i.e Milan criteria, alfa-feto model or other predictive models of recurrence at listing. b) no 
signs of HCC progression while on HCC bridging therapy and c) a waiting time > 3 months is 
expected. . GRADE III . Comment. A decision-making algorithm is proposed in Fig 1 
 
18. In patients with HCC not treated with DAA before LT, the decision and timing of DAA therapy 
after LT should be deferred after pathological assessment of the explanted liver. If the risk of 
HCC recurrence at explant pathology is high, delaying HCV treatment beyond the 2nd year post-
LT is advised, unless severe form of HCV recurrence occurs. GRADE III 
Comment In addition, this candidates might benefit from receiving a graft from a suitable anti-
HCV +ve donor. 
 
 
Q6:  Is  DAA therapy given across LT  (“bridging therapy”) a valuable option? 
 
Background 
In patients with stable clinical conditions, the full course of antiviral therapy can be generally 
completed before LT.  Nevertheless, some patients may develop an acute complication that leads 
to a rapid deterioration of their liver function.  Such patients may require an urgent LT and 
therefore this option should be specifically considered in patients who are still viremic at the 
time of LT or who did not achieve viral clearance for at least 30 days. 
 
Facts 
A single study from Italy (27) has recently shown that this strategy is feasible and very effective. 
Thirthy-one patients have been treated with SOF/RBV across transplant for up to 48 weeks and 
an SVR was achieved in 96% of the patients without major side effects. No data are yet available 
with more recent DAAs combinations.   
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Pre LT recommendations 
 
19. Bridging therapy cannot be recommended on a routine basis GRADE III 
 
20. In case of unexpected rapid deterioration of liver function while on DAA therapy, 
continuation of therapy across transplant can be considered particularly in patients who are still 
viremic. Nevertheless, the decision of continuing DAA treatment across transplant should be 
considered on a case-by case basis taking into account liver graft function, post operative renal 
function and DDI. GRADE II-3. 
 
 
Q7. How to cope with failures following DAA therapy? When is detection of resistance 
associated substitutions (RAS) a concern? 
Background. Failure to DAAs is mainly due to relapse while on-treatment virologic 
breakthrough is rare. Failure to multiple DAA regimens more often occurs in GT1a patients with 
cirrhosis, GT3 treatment experienced patients with cirrhosis, and in patients receiving shorter 
duration or RBV-free schedules. The majority of failures to DAA combinations are related to the 
presence of various proportions of HCV-RAS. A too short treatment duration or the absence of 
ribavirin are possible relevant cofactors. A cut off detection rate of RAS of at least 15% seems to 
correlate with treatment failure. NS3-4A resistance variants tend to disappear after treatment 
discontinuation. In contrast, NS5A RAS can affect treatment response in certain settings and 
these variants may persist for many years (28). The development of NS5B RAS is rare and these 
variants may also disappear over time. 
Facts. No standardized tests for the resistance of HCV to approved drugs are available as 
purchasable kits. Thus far, resistance testing relies on in-house techniques with variable 
performances. HCV drug resistance testing is not recommended in naïve patients who are not 
candidate for LT as SVR is independent from the presence of NS3-4A or NS5A RAS at 
baseline.  To date, HCV resistance testing at baseline is only recommended in the US SmPC for 
GZR/EBR when treating patients infected with genotype 1a.  In addition resistance testing may 
be useful for choosing the best treatment option in cirrhotic patients infected with genotype 3 
who fail multiple DAAs (29,14).  If resistance testing is not available for such patients, extending 
treatment and adding RBV is advisable.  
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Pre LT recommendations 
 
21. Assessment of RAS can be considered in situations where the presence of RAS will likely 
influence treatment choice and outcome. This is the case of patients with decompensated 
cirrhosis and infected with GT3 and of patients infected with subtype 1a under GZR/EBR as the 
presence of RAS justifies a longer duration of treatment or the addition of RBV.  Patients with 
RAS that do not tolerate RBV should be treated after LT. GRADE III 
 
22. For patients with decompensated cirrhosis who failed DAA therapy while on the waiting list, 
it is advisable to retreat these patients after LT.  HCV resistance testing is useful for deciding 
retreatment GRADE III. 
 
 
 
B. Post transplant phase. 
 
Q8. Which DAAs should be used after LT taking into account liver function, renal function and 
DDI? 
 
Background  
The recipient of a liver transplant has to take life-long IS and many other drugs to treat various 
co-morbidities such as diabetes mellitus, hypertension, dyslipidemia  etc (30).  All these drugs 
have to be checked for possible DDI with DAA.  Renal dysfunction is another common problem 
after LT (31) which limits the use of Sofosbuvir. 
 
Facts  
DDI with immunosuppressants.   
The main DDI between DAA and IS are shown in Table 4 and are also summarized in the EASL 
Recommendations on Treatment of Hepatitis C 2016 (6). SOF+DCV, SOF/LDV have no significant 
DDIs with any IS and antimetabolites. However potential interactions with everolimus may 
require additional monitoring. No data are available regarding possible interactions between 
SOF/VEL and major IS. Regimens containing protease inhibitors such as 2D and 3D combinations 
strongly interact with all major IS.  SIM strongly affects the metabolism of cyclosporine A (CsA) 
and, to a lesser extent, of tacrolimus (Tac) and mTOR inhibitors through CYP3A4 inhibition but it 
has no effecton mycophenolate mofetil (MMF) metabolism. A 40%-50% increase in tacrolimus 
levels is to be expected during co-administration with GZR while a 15-fold increase in GZR AUC 
and a 2-fold increase in EBR AUC is expected if co-administered with cyclosporin (8). The 
combination of SOF/LDV has minor interactions with CsA, Tac and mTOR inhibitors (6).  In 
addition to the forementioned DDI, DAAs-related HCV clearance can accelerate the metabolism 
of various IS (11) by improving the metabolic functions of the liver. 
Possible DDI between DAA and other frequently prescribed drugs (6, 32) should be taken into 
account particularly when antifungal agents, cardiovascular drugs, statins and CNS drugs are 
administered simultaneously. 
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Renal function impairment 
 
Renal dysfunction is frequent after LT either due to early postoperative complications such as 
acute tubular necrosis or as a result of long-term exposure to CNI.  HCV-related kidney injury, 
diabetes and hypertension are other possible factors impairing kidney function.  This is why the 
majority of LT recipients present a 30% GFR decline after one year from LT and a 15%–20% 
prevalence of severe renal impairment (estimated GFR<30 mL/min) after 5 years (33). 
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Recommendations post LT 
 
23. SOF+DCV, SOF/VEL can be given safely in combination with any immunosuppressant (IS). 
Since SOF/LDV moderately affects CNI/mTOR metabolism, the blood levels of IS should be 
monitored.  SIM, GZR and EBR should not be co-administered with CsA.  Monitoring blood levels 
is required when SIM, GZR and EBR are combined with Tac or mTOR inhibitors. 2D and 3D 
combinations require monitoring of all major IS. Therefore, SOF+DCV or SOF/LDV should be the 
preferred regimens after LT due to no or minimal DDI; (GRADE II-2).  
 
24. Any other drug co-administered with DAAs after LT should be checked for possible DDI, such 
as antifungal agents, antibiotics, cardiovascular drugs, CNS drugs, recreational drugs and even 
hormonal treatments. Given the frequent occurrence of arrhythmia after LT, close attention 
should be paid to patients treated with DAAs. Amiodarone should be avoided as per recent 
recommendations (6) GRADE II-2. 
 
25. SOF requires dose adjustment when the estimated GFR is below 30 mL/min. Although no 
firm recommendation can be made on the extent of the dose adjustment (6), SOF administration 
every other day is currently used with an acceptable risk/benefit ratio. Although tolerability and 
efficacy of GZR/EBR are satisfactory in patients with renal insufficiency, their use is not 
recommended after LT due to major DDI with many IS. This is also true for the 3D combo.  
GRADE II-3. 
 
26.  The issue of an increased risk of rejection following HCV clearance is of concern but needs to 
be evaluated in properly designed studies.  In the meantime close monitoring of CNI/mTOR is 
recommended particularly at the end of DAA therapy when the cessation of DDIs and the 
improved metabolic capacity of the liver may alter the exposure to various IS. (11). GRADE III 
 
 
Q9. What rate of sustained virological response is expected after treating patients for HCV 
disease recurrence? 
 
Background 
The natural course of hepatitis C is significantly accelerated in LT recipients when compared to  
immunocompetent individuals with 15% to 30% of the patients progressing to cirrhosis within 5 
years from LT and approximately 50% developing liver failure shortly thereafter. A subset of 
patients (2%-9%) may develop FCH which is defined by progressive cholestasis, very high HCV-
RNA levels, hepatocyte ballooning and rapid progression to graft failure (1-3). The management 
of HCV recurrence has been a challenge in the era of IFN-based therapies due to the combined 
effect of limited efficacy, risk of rejection (34) and high toxicity of IFN.  This sequence of events 
explains why HCV positive recipients had a 10%-reduced graft and patient survival when 
compared to other indications for LT.  However, IFN-induced SVR significantly improved 
outcomes after LT, resulting in 5-year survival rates similar to those for HCV-negative patients 
(35). As the new DAAs are much more effective and far better tolerated than IFN-based regimes, 
the outcome of LT for HCV recipients is expected to improve and become similar to that of 
patients with non HCV indications. 
 
Facts 
Considering patients with HCV recurrence after LT, the virological response to DAA has been 
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assessed in 14 studies (11-12, 14, 36–46) dealing mainly with experienced GT1 patients. Results 
from the main studies are summarized in table 5 and 6 which separate patients according to 
severity of liver disease, type of DAA regimen and HCV genotypes.   
 
Mild fibrosis stages and compensated cirrhosis (Child-Pugh A) (table 5). SVR was achieved in 
more than 90% of patients, with a good safety profile. In SOLAR 1 study (11), the combination of 
SOF/LDV+RBV (1000-1200 mg) given to patients with genotype 1 or 4 infection, resulted in SVR-
12 rates higher than 90% irrespective of treatment duration (12 or 24 weeks). Similar excellent 
SVRs of about 90% have been reported with SOF+SIM (39) in patients infected with Genotype 1, 
2 or 4 but not in those infected with genotype 3 where the SVR was only 60%. The 3D 
combination (37) was equally effective only when administered to patients without cirrhosis. 
Finally SOF+DCV was very effective in all patients but those with decompensated cirrhosis (14). 
In patients not eligible for RBV, the optimal duration of treatment is unknown but SOF/LDV for 
24 weeks in GT 1 and 4 patients seems to be a reasonable option post LT (8). Although RBV has 
been associated in most   DAA regimens after LT, its use may be problematic due to renal 
impairment. Indeed, in a recent study focusing on treatment of HCV infection after kidney 
transplantation, SOF/LDV for 12 or 24 weeks in G1/4 without RBV resulted in SVR rates of 96 to 
100% indicating that excellent results can also be achieved in immunodepressed patients 
without RBV (47)  
 
De-compensated cirrhosis. 
When considering patients with decompensated cirrhosis after LT, the SVR rates were 10% to 
30% lower than what is generally observed in patients without decompensation (11-12, 43) 
(table 6). Interestingly, although SVR rate around 85% in Child Pugh B has been reported in the 
SOLAR 1 study (11), this result was not confirmed in the SOLAR 2 study where post-LT SVR was 
95% and 100% in patients treated for 12 and 24 weeks respectively (12). An improvement in 
MELD and CP scores has been reported in 50%-60% of patients after treatment with different 
DAA combinations such as  SOF+DCV, DCV +SIM (46) or SOF/LDV + RBV (600 mg increased as 
tolerated) (11,12). On average, the improvement was of 2 points for CP score and 3 points for 
MELD score. 
 
Fibrosing cholestatic hepatitis (FCH) 
In the French multicentre cohort CUPILT (45), SVR 12 rates of 88% and 100% were obtained in 
patients with strictly defined severe forms of FCH treated with SOF+RBV or SOF+DCV±RBV (600 
mg increased as tolerated) for 24 weeks. There was no graft loss at the end of follow-up and a 
significant improvement in liver graft function was constantly observed. Studies based on 
smaller numbers of patients with FCH confirmed these excellent results in patients with FCH 
treated with SOF/LDV+RBV for 12 or 24 weeks (11, 12) (table 2 post LT).  An improvement in 
MELD and CP scores has also been reported in patients with FCH after treatment with SOF + DCV 
or DCV+ SIM (41). 
 
SVR according to genotypes 
-  Genotype 1a: when SOF+SIM is given to patients with advanced fibrosis (F3-F4) the expected 
SVR rate is about 80%  (table 5) which is at least 10% lower than that observed in  patients 
infected with genotype 1b  with or without advanced fibrosis. (39, 41-42).   
– Genotype 3: For patients without cirrhosis the combination SOF+DCV±RBV (1000-1200 
mg/die) resulted in excellent results with SVR of about 90% (15). For patients with cirrhosis the 
optimal DAA combination and duration are still to be defined. The promising SVR rate of 85% 
obtained with SOF/VEL+ RBV (14) given to immunocompetent subjects with decompensated 
cirrhosis needs to be verified in the transplant setting. 
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Recommendations  
 
27. Early treatment of FCH with SOF+DCV+RBV RBV(600 mg, increased as tolerated) for 24 
weeks or SOF/LDV +RBV RBV (600 mg, increased as tolerated) for 12 weeks is recommended 
GRADE II-1. SOF + VEL might be an alternative option, but no published data are available to 
date. (GRADE III) 
 
28. LT recipients with Genotype1/4, infection can be treated in the same way as non-transplant 
patients in terms of combinations of DAA and duration of treatment. In particular, SOF/LDV ± 
RBV or SOF+DCV for 12 weeks are recommended. The same combinations should be used for 24 
weeks in patients not eligible to RBV.   If the 3D combo is considered, careful monitoring of CNI 
trough levels is advised as strong DDI are expected. GRADE II-1.  
 
29. LT recipients with GT1a advanced fibrosis (F3-F4) should not be treated with SOF+SIM 
because of lower SVR rates (- 10%) compared to other DAA combinations. GRADE II-2  
 
30.  LT recipients with Genotype 3 infection without cirrhosis or with compensated cirrhosis, 
should be treated with SOF +DCV+RBV for 12 weeks or with SOF + DCV without RBV for 24 
weeks in case of ineligibility to RBV (GRADE II-1).  The combination of SOF/VEL±RBV for 12 
weeks should be tested urgently in the LT setting GRADE III. IFN is not recommended post-LT to 
limit the risk of IFN-induced rejection. GRADE III 
  
31. Renal function impairment and frequent use of drugs at risk of DDI 
(www.hepcdruginteractions.com) may limit the use of some DAAs in the post LT phase. DAA 
regimens should therefore be used for LT patients, as described in Recommendations 23 to 25 
GRADE II-2 
 
 
 
Q10. What is the best timing for DAA treatment after LT?   
 
Background 
In patients with active HCV replication before LT, post-transplant HCV recurrence is rapid and 
virtually universal. HCV RNA can be detected as early as a few hours post-transplant (48) and 
HCV graft reinfection subsequently leads to symptomatic HCV hepatitis between 1 to 4 months 
post-LT, with variable clinical patterns. Two different approaches can be considered to 
overcome the deleterious consequences of HCV recurrence post -LT: 
1. Very early or early DAA treatment, before biochemical manifestations of HCV recurrence 
develop i.e. pre-emptive therapy  
2. Later treatment initiated in response to biochemical and histopathological evidence of HCV 
recurrence, i.e.  clinically oriented treatment. 
In the IFN/RBV era, pre-emptive therapy was found to be ineffective and difficult to manage 
(49), due to severe hematological side effects and risk of rejection in the early post-LT period. 
Pre-emptive treatment has therefore never been adopted as the standard of care.  
3. Treatment of patients with histologically-proven HCV recurrence and minimal fibrosis (stage 
F1-F2 in the METAVIR scoring system was the norm) (50, 51).  Given the far better risk-benefit 
ratio of DAA therapy, those principles of management can be reconsidered. 
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Facts 
Results from Phase 3 studies show that excellent SVR rates > 93% can be achieved with DAA 
therapy in patients with HCV-related chronic active hepatitis and Child Pugh A cirrhosis or FCH 
post-transplant.  SVR rates are lower in patients with decompensated cirrhosis (see above). 
Although very early DAA-based pre-emptive therapy may be an attractive option to manage HCV 
recurrence, no large data are currently available on the efficacy and safety of this approach.  Of 
note, in the very early post-transplant phase optimal use of DAA may be hampered by reduced 
postoperative liver function, impaired renal function and DDI.  
 
Post LT recommendations 
 
32. At present, pre-emptive DAA therapy cannot be recommended on a routine basis. 
Prospective studies generating data on the efficacy, safety, optimal dose, timing and duration of 
pre-emptive treatment should be encouraged to assess the benefit of DAA regimens in this 
setting.  GRADE III 
 
33. DAA treatment of HCV recurrence should be considered in any LT recipient as early as  
clinically feasible, irrespective of fibrosis stage. The aim is to prevent progression to cirrhosis 
and to maximize SVR. Initiation of DAA therapy between 3 and 6 month post LT is encouraged. 
GRADE III.  
 
 
  
Q11. Can we expect a beneficial effect of HCV therapy on extra-hepatic manifestations of HCV, 
irrespective of liver injury? 
 
Background 
Active HCV replication after LT is involved in a number of extra-hepatic manifestations. HCV is a 
well-established independent risk factor for post-LT renal function impairment (33), insulin 
resistance and diabetes mellitus (52).  HCV is also a major etiological factor for type 2 
cryoglobulinemia post-LT (53) and a co-factor facilitating poly- or monoclonal B-cell 
proliferation (54-55). Diabetes mellitus and renal impairment are independent negative 
predictors of survival post-LT (33, 56). Improved renal function after achieving SVR post-LT was 
observed in the IFN/RBV era (57). In immunocompetent subjects, SVR has also been shown to 
reduce the risk of renal impairment and cardiovascular-related morbidity (58). 
 
Facts 
The impact of DAA on renal function and glucose metabolism post-LT has not yet been  evaluated 
in Phase 3 prospective clinical trials or in retrospective investigator-driven studies, which so far 
have focused on SVR, liver function and safety as the primary and secondary endpoints.  
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Recommendations  
 
34. A beneficial effect of DAA on extra-hepatic manifestations of HCV post-LT is an attractive 
hypothesis that may contribute to improved long-term outcomes. The impact of DAA treatment 
on renal function and insulin resistance post-LT should be considered as secondary endpoints in 
forthcoming prospective clinical trials or observational studies. GRADE III 
 
35. DAA treatment should be considered on an individual basis in the event of post-LT renal 
dysfunction or insulin resistance, irrespective of liver disease. GRADE III 
 
36. In the case of post-LT symptomatic mixed cryoglobulinemia or HCV-associated malignant B-
cell proliferation, DAA treatment  should be used as in the non- transplant setting (6). GRADE III  
 
 
 
Q12. Is re-transplantation for HCV-infected recipients a reliable option under DAA therapy? 
 
Background 
The utility of re-transplantation for severe HCV recurrence with decompensated cirrhosis has 
been controversial due to poor results in patients with pronounced hyperbilirubinemia (> 5 
mg/dL), renal dysfunction or MELD score > 28 (59-60). The significant burden of re-
transplantation is also a consideration in LT programmes with a high prevalence of HCV-related 
primary liver transplants, such as in southern European countries or in the USA.  
 
Facts 
It is unknown how DAA therapies may impact the outcome of re-transplantation for severe HCV 
recurrence. The issue has not been addressed in any published clinical trials.  Treatment of 
severe recurrence after primary LT has been reported to improve liver function (43-46) and may 
therefore reduce the need for re-transplantation. DAA therapies are likely to improve outcome 
because viral clearance can be achieved either before or after re-transplantation. 
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Recommendations  
 
37. Outcome of re-transplantation due to HCV-related primary graft loss should be re-assessed 
in the DAA era by prospective, observational studies which specifically target this population. 
GRADE III. 
 
38. Re-transplantation can be considered on a case-by-case basis, taking into account the 
intrinsic risks of re-transplantation and organ availability GRADE III.  
 
 
 
 
 
 
 
Q13. Can HCV-positive donors be used more extensively? 
 
Background 
Depending on the geographical area, the prevalence of HCV among organ donors ranges from 
1.4% to 5.5% (61-63) and is 2 to 3-fold higher than in the general population. Due to variations 
in HCV replication in highly selected donors, transmission of HCV is not universal. It occurs in 
roughly 50% of recipients of a graft from a HCV-positive donor.  The use of HCV-positive liver or 
kidney grafts in HCV-positive recipients has been encouraged by health authorities on the 
grounds that a 5-year liver (63-65) or kidney graft function is similar to that observed with 
organs from HCV-negative donors.  Yet HCV-positive organs remained under-used (66) because 
of reluctance on the part of health care professionals. Caution was heightened in the IFN era 
because of poorer outcomes associated with HCV-positive donors older than 50 years (67).  The 
possibility of recipients acquiring the donor HCV genotype was also of concern in the case of G1/ 
G3 donor-recipient mismatching. The high pangenotypic efficacy of DAA regimens may render 
HCV-positive liver grafts safer and may extend use of such grafts even in HCV-negative 
recipients, enabling a substantial expansion of the donor pool. This debate has been recently 
opened in the kidney transplant community.  The chair of the Ethics Committee of UNOS and the 
co-chair of the American Society of Transplant Surgeons have both recently argued in favor of 
the use of HCV-positive kidneys in HCV- negative recipients (68). 
 
Facts 
To date, DAAs have not been tested after LT in patients receiving a graft from an HCV-positive 
donor. The risk/benefit ratio of engrafting HCV-positive organs deserves re-assessment in both 
HCV-positive and HCV-negative recipients. This may be particularly important in G1 recipients 
receiving G3 liver grafts, because of  inferior SVR rates observed in G3 before the VEL becomes 
available. Using such grafts in candidates with previous SVR to anti-HCV therapy is also illogical 
and unethical although the risk/benefit ratio of such a policy may again merit assessment in 
urgent situations. 
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Recommendations  
 
39. Given the current under-use of HCV+ve organs, clinical studies under the control of ethical 
authorities should be designed for both HCV-positive and HCV-negative recipients. The aim 
would be to evaluate the impact of an anti-HCV positive donor on virological outcome, graft and 
patient survival. The impact on the donor pool should also be studied (GRADE III). 
 
40. In general, liver grafts from HCV-positive donors should not be transplanted to HCV-positive 
candidates in whom HCV has been previously eradicated before LT, for both ethical and cost-
effectiveness reasons (GRADE III). However in case of rare urgent situations, when the risk of 
death outweighs the risk of using an HCV+ve graft in a previously treated patient, a HCV positive 
organ may be considered again after obtaining candidate's  or relatives’ informed consent 
(GRADE III). 
 
41. In candidates with decompensated cirrhosis and medium MELD scores and in candidates 
with HCC in whom a long waiting time can be expected, treatment of HCV infection before LT 
should be balanced against the benefit of accelerated access to LT through the use of a HCV 
positive liver graft. (GRADE III).  
 
 
 
Conclusions:  
 
Data accumulated over the last 3 years on the use of DAAs pre and post-LT opened the door to 
considerable changes in the treatment of Hep C in the liver transplantation field. ELITA therefore 
decided to compile this series of “Consensus statements” which focus primarily on very specific LT 
issues that had not been extensively addressed previously. They have been developed in order to be of 
support to physicians and other stakeholders in charge of LT candidates and recipients when deciding 
to treat Hep C especially in some difficult situations. These  “Consensus statements” are a starting 
point and will be up-dated on a regular basis, because of the rapid changes in knowledge and rapid 
availability of new compounds. We are aware that some questions are still waiting for an answer. For 
example: Will delisting due to clinical improvement be a safe and sustainable option? What may be the 
risk of HCC in patients delisted after DAA treatment? What is the impact of DAA on extra-hepatic 
manifestations of HCV? What will the impact of DAAs on re-transplantation be? Will DAAs allow a 
wider use of HCV positive grafts? How these guidelines apply to programs with a high proportion of 
LDLT? 
 
ELITA is open to support multinational European initiatives to specifically address all these open 
questions.  
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Legenda Fig 1 
Patients listed for de-compensated cirrhosis or HCC: factors to be taken into account in the 
decision making process before DAA treatment  
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HCV patient listed for  
de-compensated cirrhosis  
Risk of pre LT death:  
Higher for  MEL >18 
Risk that DAAs may work 
 at disantvantage  
Higher for MELD >18 
Risk of removal from WL: 
Higher for « Milan out »  
or « progressing disease » or 
alfa-foeto protein > 1000 ng/mL 
Possibility of de-listing: 
Higher for MELD <18 
Risk of recurrence Post LT: 
Higher for « Milan out » 
HCV patient Listed for 
HCC 
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Table 1 GRADE system used in the  EASL Clinica Practice Guidelines. 
 
Grade evidence  
I Randomized controlled trials 
II-1 Controlled trials without randomization 
II-2 Cohort or case-control analytic studies 
II-3 Multiple time series, uncontrolled experiments 
III Opinions of respected authorities 
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Table 2a and 2b Exposure of DAA in case of impairment of liver (table 2a) or kidney  function (table 
2b)  
 
Table 2a 
 
 Liver Impairment (AUC fold-effect) Dosing guidelines 
(EMEA) 
 Mild* Moderate* Severe*  
Simeprevir  ⇑2.44 ⇑5.22 OLYSIO is not recommended in patients with moderate or severe 
hepatic impairment (Child-Pugh 
class B or C) 
Sofosbuvir 
GS331007 
 ⇑2.26 
(1.18**) 
2.43 
(1.09**) 
No dose adjustment is required 
for patients with mild, moderate, 
or severe hepatic impairment 
(CPT Class A, B, or C). 
Ledipasvir no adjustment no adjustment ↔ No dose adjustment. Treatment 
with Harvoni should be guided by 
an assessment of the potential 
benefits and risks for the 
individual patient 
Paritaprevir/r ⇓0.52 ⇑1.62 ⇑10.23 Viekirax +/- Exviera is not 
recommended in patients with 
moderate hepatic impairment 
(Child-Pugh B) and is 
contraindicated in patients with 
severe hepatic impairment (Child-
Pugh C) 
Ombitasvir 0.92 0.70 0.45 
Dasabuvir 1.17 0.84 4.19 
Daclatasvir ⇓0.57 ⇓ 0.62 
unbound  
⇓0.64 
unbound  
No dose adjustment for CPT 
Class A or B.  Lower SVR rates 
were observed with CPT C 
compared with CPT A or B in 
ALLY-1, thus treatment for 24 
weeks is recommended (EASL 
guidelines) 
Velpatasvir  ↔ ↔ No dose adjustment of Epclusa is 
required for patients with mild, 
moderate, or severe hepatic 
impairment (CPT Class A, B, or 
C). Safety and efficacy of 
Epclusa have been assessed in 
patients with CPT Class B 
cirrhosis, but not in patients with 
CPT Class C cirrhosis 
Grazoprevir ⇑1.66 ⇑4.82 ⇑11.68 No dose adjustment of ZEPATIER is required in patients 
with mild hepatic impairment 
(Child-Pugh A). ZEPATIER is 
contraindicated in patients with 
moderate or severe hepatic 
impairment (Child-Pugh B or C) 
Elbasvir ⇓0.61 ⇓0.72 ⇓0.88 
  
 
 
37 
37 
 
* Typically Mid = CPT A, Moderate = CPT B, Severe = CPT C 
** Cmax reduced ↔ 
 
 
 
 Renal Impairment (AUC fold-effect) 
 Mild 
eGFR 60-90* 
Moderate 
eGFR 30-60* 
Severe 
eGFR < 30 
Haemodialysis 
Simeprevir   ↑1.62 ND
†
 
Sofosbuvir 
(GS331007) 
↑1.61* 
(↑1.55)* 
↑2.07* 
(↑1.88)* 
↑2.71* 
(↑5.51)* 
↑1.28, 1.60** 
(↑13.8, 21.7)** 
Ledipasvir   ↔ ND
†
 
Paritaprevir/r ↑1.19 ↑1.33 ↑1.45 ND 
Ombitasvir ↔ ↔ ↔ ND 
Dasabuvir ↑1.21 ↑1.37 ↑1.50 ND 
Daclatasvir ↑1.18
∇
 ↑1.39
∇
 ↑1.51
∇
 ↑1.27
∇
 
Velpatasvir   ↑1.50 ND 
Gazoprevir   ↑1.65 ↔ 
Elbasvir   ↑1.86 ↔ 
 
 
 
* eGFR: Mild typically in the range 50 or 60 mil/min to 80 or 90. Moderate: typically in the range 30 to 
50 or 60 ml/min Severe <30 ml/min 
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Table 3. DAAs in patients with decompensated cirrhosis  
 
 
 
 
 
Afdhal 
Ref.10 
Charlton 
Ref.11 
Manns 
Ref.12 
Foster 
Ref.13 
Poordad 
Ref.15 
Curry  
Ref 14 
Pts, N 50  108 160 467 60 267 
Therapy SOF+
R 
SOF/LDV+r
R 
SOF/LDV+
R 
SOF/LDV+R 
SOF+DVC+R 
SOF+DCV+R SOF/VPV±R 
Duration Tx 48w 12w (53 pts) 
24w (55 pts) 
12w (78pts) 
24w (82pts) 
12w 12w 12 w (180 pts) 
24 w (87pts) 
Child A, N of 
pts 
18 0 0 112 12 16 
Child B, N of 
pts 
32 
59 78 
309 32 240 
Child C, N of 
pts 49 82 
46 16 11 
MELD >15: 4 
pts 
 >15: 41 pts Mean (range) 
11.9 (6-36) 
>15: 14 pts >15:13 pts 
Tx-experinced 
% 
80%  78% 47.1% 60% 80% 
GT1a-1b, % 
GT2-3-4, % 
38%-
30% 
32% 
 47.5%-
42.5% 
GT4: 10% 
GT1 50.3% 
Other: 49.7% 
57%-18% 
8%-17% 
78% 
22% 
SVR12 % 
 Child A% 
 Child B-C% 
78% 
 68% 
88% 85-88% SOF/LDV: 
80% 
SOF+DCV:74
% 
92% 
94%-56% 
SOF/VPV 
83% 
SOF/VPV+RBV: 
94%  
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Table 4 Drug-drug interactions between HCV DAAs and immunosuppressants 
 
 SOF SOF/ 
LDV 
SOF/ 
VPV 
3D GZR/ 
EBR 
DCV SIM 
 
Aza 
       
CsA 
       
Etanercept 
       
Everolimus 
       
Mycofenolate 
       
Sirolimus        
Tacrolimus 
       
 
 
Color legend 
 
No clinically significant interaction expected 
 
Potential interaction that may require a dosage adjustment 
 
These drugs should not be co-administered 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 5: DAA for HCV recurrence after liver transplantation in mild fibrosis and compensated 
cirrhosis 
 
 Charlton 
(38) 
Gutteriez 
(39) 
Faisal  
(40) 
Brown  
(41) 
  
Pungpagong 
(42) 
Kwo  
CORAL-1 
(37) 
Poordad 
Ally-1 (15) 
Charlton 
Solar 1 (11) 
Manns 
Solar 2 (12) 
Pts (n) 40 61 120 151 123 34 53 162 168 
Therapy SOF+RBV 
24 w 
SOF/SIM 
±RBV 12w 
SOF+SIM 
±RBV 12w 
Or 
SOF/RBV 
24w or 
SOF/LED 
12 to 24w 
SOF+SIM 
±RBV 
(21%, 
starting 
dose 800 
mg) 12w 
SOF+SIM/ 
±RBV 12w 
3D combo ** 
+RBV  24w 
SOF+DCV+ 
RBV 12w 
SOF/LED 
+RBV  
12 vs 24 w 
SOF/LED 
+RBV 
12  vs 24 w 
Genotype 
1-4/2-3 
83% 
(1a55%-
1b28%)-
3%/15% 
All GT1 
1a:57% 
1b: 43% 
GT1 83% All pts 
GT1* 
GT1a  
56.3% 
All GT 1* 
GT1a  60% 
G1b   35% 
 
 
GT1a  85% 
GT1b  
GT1: 77% 
   1a: 58% 
   1b: 19% 
GT3: 21% 
GT1  99% 
G1a  70% 
G1b  29% 
 
GT1: 87% 
   1a: 49% 
   1b: 38% 
GT4: 13% 
  
 
 
40 
40 
G1b   
26.9% 
 
GT6: 2%  
Treatment-
experienced 
88% 69% 82% 56.3% 82% 71% 58% 82% 81.5% 
F3/F4 62% 38% 48% 64.2% (F4) 30% 0 55% 29.6% (F4) 40% (F4) 
 
SVR 12 
Overall 
 
70% 93.4% 85% 88% 90% 97% 94% 97% 
Similar 
between 12 vs 
24w 
97% 
 
GT 1 GT1a: 
73% 
GT1b 55% 
GT1a: 89% 
GT1b 100% 
GT1a 83% 
GT1B 
100% 
GT1a 85% 
GT1b: 94% 
 
GT1a: 86% 
GT1b 95% 
(ns) 
 
GT1a: 97% 
GT1b 100 % 
(ns) 
GT1 95% 
GT1a: 97% 
GT1b 90 % 
(ns) 
NA GT1: 97% 
GT3/4 100%/- NA 100% NA  NA 91%/- NA -/95% 
F0-F2/F3-F4 NA  91%/81% 93%/86% 93% vs 81% 
p=0.05 
NA NA Similar 
SVR 
97%/97%¥ 
GT1aF3-4 NA 67%  82% 71% (vs 
93%) 
NA NA NA NA 
Relapse/ 
Breakthrough 
30%/- Higher 
Among 
GT1a F3/4 
6%/0.8% 7%/0.6% 6.5%/2.4% 3%/- NA 1.2%/0  
SAE 5% 
Anemia 
20% 
low Severe 
anemia 
13% 
11.9% 1.6% 6% 0% 15%  
DCV : daclatasvir, GT : genotype, LED: ledispavir, NA : not applicable, ns : not significant, Pts : patients, RBV : ribavirin, SAE : serious 
adverse event, SOF : sofosbuvir, SIM : simeprevir. 
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Table 6:  DAA for severe HCV recurrence after liver transplantation de- compensated cirrhosis and fibrosing 
cholestatic hepatitis 
 
 Fibrosing Cholestatic Hepatitis De-compensated cirrhosis  
 Forns§ 
(43) 
Charlton 
+ Manns 
Solar 1 + 2  
(11, 12 ) 
Leroy 
(CUPILT) 
(45) 
Fontana* 
(46) 
Charlton 
Solar 1 (11) 
Manns 
Solar 2 (12) 
Pts (n) 52 11 22 97 61 53 
Therapy SOF+RBV or 
SOF+RBV+PEG 
24w 
SOF+ LEDI +RBV 
12 vs 24 w 
SOF+RBV+
/- PEG or 
SOF/DAC 
 24w 
DCV+SOF+/-
RBV(n=77);
DCV/SIM+/-
RBV (n=18) 
24w  
SOF/LED+RBV 
12 vs 24 w 
SOF/LED 
+ RBV 
12  vs 24 w 
Genotype  
1-4/2-3 
GT1: 86% 
GT1a : 42% 
GT1b : 44% 
GT2/3: 4% 
GT4: 10% 
All GT1 
GT1a : 82% 
GT1b : 18% 
  GT 1: 93% 
GT1a: 39% 
G1b:   47% 
GT3 : 2% 
GT4: 4% 
 
GT1  98.6% 
G1a  74% 
G1b  24.6% 
G4: 1.4% 
GT1: 85.6% 
   1a: 49% 
   1b: 39.6% 
GT4: 11.4% 
 
Treatment-
experienced 
NA 82%   55% before 
LT 
37% after LT 
85% 83% 
Child Pugh 
B/C 
NA NA  NA 31%/12% 
Cholestatic 
pattern : 
37% 
85%/15% 85%/15% 
 
SVR 12 
Overall 
 
73% 100% 
Similar SVR 
 in w12 & w24 
88% vs 
100%   
SOF/RBV 
vs 
SOF+DCV+
RBV 
 
87% 
DCV+SOF vs 
DCV+SIM 
91% vs 72% 
(p=0.047) 
RBV+ vs 
RBV- : ns 
83.6% 
  12 vs 24w 
80% vs 86.6% 
92.4% 
12 vs 24w 
88% vs 93.1% 
 
GT 1 
NA GT1a: 100% 
GT1b: 100% 
   
NA 
 
NA 
 
GT1: 93.6% 
   
GT3/4 NA NA    NA -/83.3%** 
Child Pugh 
B/C 
NA NA NA NA 
Cholestatic 
vs non 
cholestatic 
86%vs 87% 
p>0.99 
86.5% vs 66.6%* 
 
97.7% 
vs 62.5% ¥ 
GT1aF3-4 NA NA NA NA NA NA 
Relapse/ 
Breakthrough 
8%/- 0/0   2%/5% 
(All with 
DCV+SIM) 
6.5%/0 1.8%/- 
SAE 2 % drug 
discontinuation 
due to SAE 
Death 13% 
 27% 
No study drug 
discontinuation 
  
  20% 
2 SAE 
possibly 
related to 
DAA 
No drug 
interruption 
No SAE leading to study 
drug discontinuation  
26% 
Improvement 
of liver 
function 
 
Decrease in 
bilirubin from 
4.7 to 0.7mg/dL 
Median of 8 
MELD points 
improvement 
Normalization of 
INR , bilirubin 
and Albumin on 
posttreatment 
week 4 
100% 
Normalizat
ion of LFT 
in the 
CUPILT 
study 
Average CP 
/MELD 
improvement
: 1 /2.3pts 
% of 
CP/MELD 
deterioration 
: 13%/17% 
% of CP/MELD 
improvement: 59%/45% 
Average CP/MELD 
improvement :2.2 /3.3pt 
% of CP/MELD 
deterioration:  7%/18% 
(only in CP B) 
Decrease in bilirubin by 0.5  
& 1.5 mg/dL, in CPB and 
CPC , respectively, increase 
in albumin by 0.5 g/dL 
% of CP/MELD 
improvement 
77%/60% 
Average CP/MELD 
improvement :   
1.8/3.5pt 
% of CP/MELD 
deterioration:  
2.5%/23%   
 
§ Early severe recurrent hepatitis; * 43% CP B/C, 37% cholestatic pattern on cirrhosis; * Only 9 Child Pugh C patients; 
** only 6 GT4 pts; ¥ only  8 Child Pugh C pts.  
CP : Child-Pugh, DCV : daclatasvir, GT : genotype, LED: ledispavir , NA : not applicable, ns : not significant, pt: points, PEG : pegylated 
Interferon, Pts : patients, RBV : ribavirin, SAE : serious adverse event, SOF : sofosbuvir, SIM : simeprevir, SVR : sustained virological 
response. 
 
